Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases
Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 2024-09, Vol.44 (9), p.1733-1737 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1737 |
|---|---|
| container_issue | 9 |
| container_start_page | 1733 |
| container_title | Rheumatology international |
| container_volume | 44 |
| creator | Panagiotopoulos, Alexandros Fragoulis, George E. Arida, Aikaterini Bournia, Vassiliki-Kalliopi Evangelatos, Gerasimos Fragkiadaki, Kalliopi Kravvariti, Evrydiki Laskari, Katerina Mylona, Maria Michalakeas, Nikolaos Papazoglou, Nikolaos Pappa, Maria Poulia, Vassiliki Panopoulos, Stylianos Ziarangali, Sevastiani Papatheodorou, Vasileios Tektonidou, Maria G. Sfikakis, Petros P. |
| description | Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls. Logistic regression analysis was performed to assess potential milder re-infection versus primary infection severity, adjusting for study group, demographics (age, sex), vaccination status, body mass index, smoking, and comorbidities. 23 and 7 out of 167 re-infected SRD patients experienced two and three re-infections, respectively, which were comparable to the re-infection rates in controls (two: 32; and three: 2) who also had comparable COVID-19 vaccination history (89% and 95% vaccinated, respectively). In the initial infection, patients with SRDs were hospitalized (7.2% versus 1.8%,
p
= 0.017), and had received antiviral treatment (16.1% versus 4.7%,
p
0.05) between patients and controls at the first re-infection, as well as during the second and third re-infection; no deaths were recorded. Perceived severity of re-infections was also comparable between patients and controls (
p
= 0.847) and among those on biologic DMARDs or not (
p
= 0.482). In multivariable analysis, neither SRDs presence nor demographics or comorbidities were associated with COVID-19 re-infection severity. COVID-19 re-infection severity (patient-perceived/hospitalizations/deaths) did not differ between SRDs and controls. |
| doi_str_mv | 10.1007/s00296-024-05573-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022567536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3022567536</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-abaf8464f39b243910e8cad561a66652f6f3465b9e51a3477ba0dc9913bdf9b33</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EoqXwB1ggS2zYGPyKE7NDw6tSpdkUxM5ynOuOyyQefB2N-u_JMIVWLLqy5fOdc698CHkp-FvBefsOOZfWMC41403TKrZ_RE6FVi0Thv94fO9-Qp4hXnMuWmP4U3KiukZ3lnen5Od6riGPgDRHulp_P__IhKUFWJoihJryhO-pp5imqy2wAFOFQkPe5FIPDmFauvM1Le9I96luKN5ghTEFWjYwj4sU6JAQPAI-J0-i3yK8uD3PyLfPny5XX9nF-sv56sMFC0qaynzvY6eNjsr2UisrOHTBD40R3hjTyGii0qbpLTTCK922vedDsFaofoi2V-qMvDnm7kr-NQNWNyYMsN36CfKMTnEpG9M2yizo6__Q6zyXadluoazR0truQMkjFUpGLBDdrqTRlxsnuDtU4Y5VuKUK96cKt19Mr26j536E4Z_l798vgDoCuEjTFZS72Q_E_ga_ApP5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3096429986</pqid></control><display><type>article</type><title>Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Panagiotopoulos, Alexandros ; Fragoulis, George E. ; Arida, Aikaterini ; Bournia, Vassiliki-Kalliopi ; Evangelatos, Gerasimos ; Fragkiadaki, Kalliopi ; Kravvariti, Evrydiki ; Laskari, Katerina ; Mylona, Maria ; Michalakeas, Nikolaos ; Papazoglou, Nikolaos ; Pappa, Maria ; Poulia, Vassiliki ; Panopoulos, Stylianos ; Ziarangali, Sevastiani ; Papatheodorou, Vasileios ; Tektonidou, Maria G. ; Sfikakis, Petros P.</creator><creatorcontrib>Panagiotopoulos, Alexandros ; Fragoulis, George E. ; Arida, Aikaterini ; Bournia, Vassiliki-Kalliopi ; Evangelatos, Gerasimos ; Fragkiadaki, Kalliopi ; Kravvariti, Evrydiki ; Laskari, Katerina ; Mylona, Maria ; Michalakeas, Nikolaos ; Papazoglou, Nikolaos ; Pappa, Maria ; Poulia, Vassiliki ; Panopoulos, Stylianos ; Ziarangali, Sevastiani ; Papatheodorou, Vasileios ; Tektonidou, Maria G. ; Sfikakis, Petros P.</creatorcontrib><description>Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls. Logistic regression analysis was performed to assess potential milder re-infection versus primary infection severity, adjusting for study group, demographics (age, sex), vaccination status, body mass index, smoking, and comorbidities. 23 and 7 out of 167 re-infected SRD patients experienced two and three re-infections, respectively, which were comparable to the re-infection rates in controls (two: 32; and three: 2) who also had comparable COVID-19 vaccination history (89% and 95% vaccinated, respectively). In the initial infection, patients with SRDs were hospitalized (7.2% versus 1.8%,
p
= 0.017), and had received antiviral treatment (16.1% versus 4.7%,
p
< 0.001) more frequently than controls. However, hospitalizations (1.8% vs 0.6%) and antiviral treatment (7.8% vs 3.5%) did not differ (
p
> 0.05) between patients and controls at the first re-infection, as well as during the second and third re-infection; no deaths were recorded. Perceived severity of re-infections was also comparable between patients and controls (
p
= 0.847) and among those on biologic DMARDs or not (
p
= 0.482). In multivariable analysis, neither SRDs presence nor demographics or comorbidities were associated with COVID-19 re-infection severity. COVID-19 re-infection severity (patient-perceived/hospitalizations/deaths) did not differ between SRDs and controls.</description><identifier>ISSN: 1437-160X</identifier><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-024-05573-w</identifier><identifier>PMID: 38548908</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Comorbidity ; COVID-19 - complications ; COVID-19 - epidemiology ; COVID-19 - mortality ; COVID-19 vaccines ; Female ; Hospitalization ; Hospitalization - statistics & numerical data ; Humans ; Immunization ; Infections ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Observational Research ; Patients ; Reinfection - epidemiology ; Retrospective Studies ; Rheumatic diseases ; Rheumatic Diseases - drug therapy ; Rheumatic Diseases - epidemiology ; Rheumatology ; SARS-CoV-2 ; Severity of Illness Index</subject><ispartof>Rheumatology international, 2024-09, Vol.44 (9), p.1733-1737</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-abaf8464f39b243910e8cad561a66652f6f3465b9e51a3477ba0dc9913bdf9b33</cites><orcidid>0000-0003-3612-9394 ; 0000-0001-5484-2930 ; 0000-0002-2162-1362 ; 0000-0002-3720-5996 ; 0000-0003-4932-7023 ; 0000-0002-6477-6583 ; 0009-0006-1175-2285 ; 0000-0003-2238-0975 ; 0000-0003-3822-3093 ; 0000-0003-3258-6627 ; 0000-0003-1296-0693 ; 0000-0002-0420-6538 ; 0000-0003-4330-3266</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-024-05573-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-024-05573-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38548908$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Panagiotopoulos, Alexandros</creatorcontrib><creatorcontrib>Fragoulis, George E.</creatorcontrib><creatorcontrib>Arida, Aikaterini</creatorcontrib><creatorcontrib>Bournia, Vassiliki-Kalliopi</creatorcontrib><creatorcontrib>Evangelatos, Gerasimos</creatorcontrib><creatorcontrib>Fragkiadaki, Kalliopi</creatorcontrib><creatorcontrib>Kravvariti, Evrydiki</creatorcontrib><creatorcontrib>Laskari, Katerina</creatorcontrib><creatorcontrib>Mylona, Maria</creatorcontrib><creatorcontrib>Michalakeas, Nikolaos</creatorcontrib><creatorcontrib>Papazoglou, Nikolaos</creatorcontrib><creatorcontrib>Pappa, Maria</creatorcontrib><creatorcontrib>Poulia, Vassiliki</creatorcontrib><creatorcontrib>Panopoulos, Stylianos</creatorcontrib><creatorcontrib>Ziarangali, Sevastiani</creatorcontrib><creatorcontrib>Papatheodorou, Vasileios</creatorcontrib><creatorcontrib>Tektonidou, Maria G.</creatorcontrib><creatorcontrib>Sfikakis, Petros P.</creatorcontrib><title>Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls. Logistic regression analysis was performed to assess potential milder re-infection versus primary infection severity, adjusting for study group, demographics (age, sex), vaccination status, body mass index, smoking, and comorbidities. 23 and 7 out of 167 re-infected SRD patients experienced two and three re-infections, respectively, which were comparable to the re-infection rates in controls (two: 32; and three: 2) who also had comparable COVID-19 vaccination history (89% and 95% vaccinated, respectively). In the initial infection, patients with SRDs were hospitalized (7.2% versus 1.8%,
p
= 0.017), and had received antiviral treatment (16.1% versus 4.7%,
p
< 0.001) more frequently than controls. However, hospitalizations (1.8% vs 0.6%) and antiviral treatment (7.8% vs 3.5%) did not differ (
p
> 0.05) between patients and controls at the first re-infection, as well as during the second and third re-infection; no deaths were recorded. Perceived severity of re-infections was also comparable between patients and controls (
p
= 0.847) and among those on biologic DMARDs or not (
p
= 0.482). In multivariable analysis, neither SRDs presence nor demographics or comorbidities were associated with COVID-19 re-infection severity. COVID-19 re-infection severity (patient-perceived/hospitalizations/deaths) did not differ between SRDs and controls.</description><subject>Adult</subject><subject>Aged</subject><subject>Comorbidity</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 vaccines</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Observational Research</subject><subject>Patients</subject><subject>Reinfection - epidemiology</subject><subject>Retrospective Studies</subject><subject>Rheumatic diseases</subject><subject>Rheumatic Diseases - drug therapy</subject><subject>Rheumatic Diseases - epidemiology</subject><subject>Rheumatology</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><issn>1437-160X</issn><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhS0EoqXwB1ggS2zYGPyKE7NDw6tSpdkUxM5ynOuOyyQefB2N-u_JMIVWLLqy5fOdc698CHkp-FvBefsOOZfWMC41403TKrZ_RE6FVi0Thv94fO9-Qp4hXnMuWmP4U3KiukZ3lnen5Od6riGPgDRHulp_P__IhKUFWJoihJryhO-pp5imqy2wAFOFQkPe5FIPDmFauvM1Le9I96luKN5ghTEFWjYwj4sU6JAQPAI-J0-i3yK8uD3PyLfPny5XX9nF-sv56sMFC0qaynzvY6eNjsr2UisrOHTBD40R3hjTyGii0qbpLTTCK922vedDsFaofoi2V-qMvDnm7kr-NQNWNyYMsN36CfKMTnEpG9M2yizo6__Q6zyXadluoazR0truQMkjFUpGLBDdrqTRlxsnuDtU4Y5VuKUK96cKt19Mr26j536E4Z_l798vgDoCuEjTFZS72Q_E_ga_ApP5</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Panagiotopoulos, Alexandros</creator><creator>Fragoulis, George E.</creator><creator>Arida, Aikaterini</creator><creator>Bournia, Vassiliki-Kalliopi</creator><creator>Evangelatos, Gerasimos</creator><creator>Fragkiadaki, Kalliopi</creator><creator>Kravvariti, Evrydiki</creator><creator>Laskari, Katerina</creator><creator>Mylona, Maria</creator><creator>Michalakeas, Nikolaos</creator><creator>Papazoglou, Nikolaos</creator><creator>Pappa, Maria</creator><creator>Poulia, Vassiliki</creator><creator>Panopoulos, Stylianos</creator><creator>Ziarangali, Sevastiani</creator><creator>Papatheodorou, Vasileios</creator><creator>Tektonidou, Maria G.</creator><creator>Sfikakis, Petros P.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3612-9394</orcidid><orcidid>https://orcid.org/0000-0001-5484-2930</orcidid><orcidid>https://orcid.org/0000-0002-2162-1362</orcidid><orcidid>https://orcid.org/0000-0002-3720-5996</orcidid><orcidid>https://orcid.org/0000-0003-4932-7023</orcidid><orcidid>https://orcid.org/0000-0002-6477-6583</orcidid><orcidid>https://orcid.org/0009-0006-1175-2285</orcidid><orcidid>https://orcid.org/0000-0003-2238-0975</orcidid><orcidid>https://orcid.org/0000-0003-3822-3093</orcidid><orcidid>https://orcid.org/0000-0003-3258-6627</orcidid><orcidid>https://orcid.org/0000-0003-1296-0693</orcidid><orcidid>https://orcid.org/0000-0002-0420-6538</orcidid><orcidid>https://orcid.org/0000-0003-4330-3266</orcidid></search><sort><creationdate>20240901</creationdate><title>Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases</title><author>Panagiotopoulos, Alexandros ; Fragoulis, George E. ; Arida, Aikaterini ; Bournia, Vassiliki-Kalliopi ; Evangelatos, Gerasimos ; Fragkiadaki, Kalliopi ; Kravvariti, Evrydiki ; Laskari, Katerina ; Mylona, Maria ; Michalakeas, Nikolaos ; Papazoglou, Nikolaos ; Pappa, Maria ; Poulia, Vassiliki ; Panopoulos, Stylianos ; Ziarangali, Sevastiani ; Papatheodorou, Vasileios ; Tektonidou, Maria G. ; Sfikakis, Petros P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-abaf8464f39b243910e8cad561a66652f6f3465b9e51a3477ba0dc9913bdf9b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Comorbidity</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 vaccines</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Observational Research</topic><topic>Patients</topic><topic>Reinfection - epidemiology</topic><topic>Retrospective Studies</topic><topic>Rheumatic diseases</topic><topic>Rheumatic Diseases - drug therapy</topic><topic>Rheumatic Diseases - epidemiology</topic><topic>Rheumatology</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Panagiotopoulos, Alexandros</creatorcontrib><creatorcontrib>Fragoulis, George E.</creatorcontrib><creatorcontrib>Arida, Aikaterini</creatorcontrib><creatorcontrib>Bournia, Vassiliki-Kalliopi</creatorcontrib><creatorcontrib>Evangelatos, Gerasimos</creatorcontrib><creatorcontrib>Fragkiadaki, Kalliopi</creatorcontrib><creatorcontrib>Kravvariti, Evrydiki</creatorcontrib><creatorcontrib>Laskari, Katerina</creatorcontrib><creatorcontrib>Mylona, Maria</creatorcontrib><creatorcontrib>Michalakeas, Nikolaos</creatorcontrib><creatorcontrib>Papazoglou, Nikolaos</creatorcontrib><creatorcontrib>Pappa, Maria</creatorcontrib><creatorcontrib>Poulia, Vassiliki</creatorcontrib><creatorcontrib>Panopoulos, Stylianos</creatorcontrib><creatorcontrib>Ziarangali, Sevastiani</creatorcontrib><creatorcontrib>Papatheodorou, Vasileios</creatorcontrib><creatorcontrib>Tektonidou, Maria G.</creatorcontrib><creatorcontrib>Sfikakis, Petros P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Panagiotopoulos, Alexandros</au><au>Fragoulis, George E.</au><au>Arida, Aikaterini</au><au>Bournia, Vassiliki-Kalliopi</au><au>Evangelatos, Gerasimos</au><au>Fragkiadaki, Kalliopi</au><au>Kravvariti, Evrydiki</au><au>Laskari, Katerina</au><au>Mylona, Maria</au><au>Michalakeas, Nikolaos</au><au>Papazoglou, Nikolaos</au><au>Pappa, Maria</au><au>Poulia, Vassiliki</au><au>Panopoulos, Stylianos</au><au>Ziarangali, Sevastiani</au><au>Papatheodorou, Vasileios</au><au>Tektonidou, Maria G.</au><au>Sfikakis, Petros P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>44</volume><issue>9</issue><spage>1733</spage><epage>1737</epage><pages>1733-1737</pages><issn>1437-160X</issn><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Data on COVID-19 re-infections in patients with systemic rheumatic diseases (SRDs) are lacking. We aimed to describe the course and outcomes of COVID-19 re-infections in these patients versus controls. In this single-center retrospective study, we included 167 consecutive SRD patients with at least one COVID-19 re-infection (mean age 47.3 years, females 70.7%). SRD patients were compared in terms of patient-perceived COVID-19 re-infection severity and hospitalizations/deaths with 167 age/sex-matched non-SRD controls. Logistic regression analysis was performed to assess potential milder re-infection versus primary infection severity, adjusting for study group, demographics (age, sex), vaccination status, body mass index, smoking, and comorbidities. 23 and 7 out of 167 re-infected SRD patients experienced two and three re-infections, respectively, which were comparable to the re-infection rates in controls (two: 32; and three: 2) who also had comparable COVID-19 vaccination history (89% and 95% vaccinated, respectively). In the initial infection, patients with SRDs were hospitalized (7.2% versus 1.8%,
p
= 0.017), and had received antiviral treatment (16.1% versus 4.7%,
p
< 0.001) more frequently than controls. However, hospitalizations (1.8% vs 0.6%) and antiviral treatment (7.8% vs 3.5%) did not differ (
p
> 0.05) between patients and controls at the first re-infection, as well as during the second and third re-infection; no deaths were recorded. Perceived severity of re-infections was also comparable between patients and controls (
p
= 0.847) and among those on biologic DMARDs or not (
p
= 0.482). In multivariable analysis, neither SRDs presence nor demographics or comorbidities were associated with COVID-19 re-infection severity. COVID-19 re-infection severity (patient-perceived/hospitalizations/deaths) did not differ between SRDs and controls.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38548908</pmid><doi>10.1007/s00296-024-05573-w</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-3612-9394</orcidid><orcidid>https://orcid.org/0000-0001-5484-2930</orcidid><orcidid>https://orcid.org/0000-0002-2162-1362</orcidid><orcidid>https://orcid.org/0000-0002-3720-5996</orcidid><orcidid>https://orcid.org/0000-0003-4932-7023</orcidid><orcidid>https://orcid.org/0000-0002-6477-6583</orcidid><orcidid>https://orcid.org/0009-0006-1175-2285</orcidid><orcidid>https://orcid.org/0000-0003-2238-0975</orcidid><orcidid>https://orcid.org/0000-0003-3822-3093</orcidid><orcidid>https://orcid.org/0000-0003-3258-6627</orcidid><orcidid>https://orcid.org/0000-0003-1296-0693</orcidid><orcidid>https://orcid.org/0000-0002-0420-6538</orcidid><orcidid>https://orcid.org/0000-0003-4330-3266</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1437-160X |
| ispartof | Rheumatology international, 2024-09, Vol.44 (9), p.1733-1737 |
| issn | 1437-160X 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3022567536 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Comorbidity COVID-19 - complications COVID-19 - epidemiology COVID-19 - mortality COVID-19 vaccines Female Hospitalization Hospitalization - statistics & numerical data Humans Immunization Infections Male Medicine Medicine & Public Health Middle Aged Observational Research Patients Reinfection - epidemiology Retrospective Studies Rheumatic diseases Rheumatic Diseases - drug therapy Rheumatic Diseases - epidemiology Rheumatology SARS-CoV-2 Severity of Illness Index |
| title | Outcomes of COVID-19 re-infections: a single-center cohort of 167 patients with systemic rheumatic diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A26%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20COVID-19%20re-infections:%20a%20single-center%20cohort%20of%20167%20patients%20with%20systemic%20rheumatic%20diseases&rft.jtitle=Rheumatology%20international&rft.au=Panagiotopoulos,%20Alexandros&rft.date=2024-09-01&rft.volume=44&rft.issue=9&rft.spage=1733&rft.epage=1737&rft.pages=1733-1737&rft.issn=1437-160X&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-024-05573-w&rft_dat=%3Cproquest_cross%3E3022567536%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3096429986&rft_id=info:pmid/38548908&rfr_iscdi=true |